

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5831716

| | |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| SUBMISSION TYPE: | NEW ASSIGNMENT |
| NATURE OF CONVEYANCE: | ASSIGNMENT |
| CONVEYING PARTY DATA | |
| Name | Execution Date |
| RETO NAEF | 10/21/2019 |
| HERMANN TENOR | 10/21/2019 |
| RECEIVING PARTY DATA | |
| Name: | TOPADUR PHARMA AG |
| Street Address: | GRABENSTRASSE 11A |
| City: | SCHLIEREN |
| State/Country: | SWITZERLAND |
| Postal Code: | 8952 |
| PROPERTY NUMBERS Total: 1 | |
| Property Type | Number |
| Application Number: | 16615283 |
| CORRESPONDENCE DATA | |
| Fax Number: | (703)712-8525 |
| <i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i> | |
| Phone: | (703) 712-8531 |
| Email: | admin@medlerferro.com, docketing@medlerferro.com |
| Correspondent Name: | MEDLER FERRO WOODHOUSE & MILLS PLLC |
| Address Line 1: | 8201 GREENSBORO DRIVE |
| Address Line 2: | SUITE 1060 |
| Address Line 4: | MCLEAN, VIRGINIA 22102 |
| ATTORNEY DOCKET NUMBER: | 0192-0099US1 |
| NAME OF SUBMITTER: | CYNTHIA M BOUCHEZ |
| SIGNATURE: | /Cynthia M. Bouchez #47,438/ |
| DATE SIGNED: | 11/21/2019 |
| Total Attachments: 2 | |
| source=P5193US00 (0192-0099US1) - Assignment - Inventor to Applicant#page1.tif | |
| source=P5193US00 (0192-0099US1) - Assignment - Inventor to Applicant#page2.tif | |

ASSIGNMENT

In consideration of good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, **Reto NAEF and Hermann TENOR** (the undersigned inventors) hereby sell and assign to **TOPADUR PHARMA AG**, having a business address at Grabenstrasse 11A 8952 Schlieren, Switzerland (the Assignee), their entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages, for the United States of America (as defined in 35 U.S.C. § 100) and throughout the world,

(a) in the invention(s) known as **NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF** (also known as International Application No. PCT/EP2018/063339, filed May 22, 2018), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent applications listed above in part (a), including non-provisional applications, continuing (continuation, divisional, or continuation-in-part) applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent applications listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent applications, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor, and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the undersigned inventors had this assignment and sale not been made.


Each undersigned inventor agrees to execute all papers necessary in connection with the application(s) and any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.


Each undersigned inventor agrees to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any non-provisional, continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

Each undersigned inventor hereby represents that he has full right to convey his entire interest herein assigned, and that he has not executed, and will not execute, any agreement in conflict therewith.

Each undersigned inventor hereby grants the attorneys associated with Customer Number 56,719, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite his name.

Date: 21-10-2019 Signature of Inventor: 
Reto NAEF

Date: 2/10/2019 Signature of Inventor: 
Hermann TENOR

4838-8754-8329, v. 1